NRD
AUPH icon

Nebula Research & Development’s Aurinia Pharmaceuticals AUPH Stock Holding History

Nebula Research & Development’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,391
Closed -$226K – 489
2023
Q2 		$226K Buy
23,391
+10,578
+83% +$110K 0.17% 249
2023
Q1 		$140K Buy
+12,813
New +$113K 0.25% 192

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nebula Research & Development's AUPH Position: Q3 2023 in Review

Nebula Research & Development sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 23,391 shares — an estimated $226K sold.

Nebula Research & Development first reported a position in AUPH in Q1 2023 and held it in 2 quarters. The position peaked at $226K in Q2 2023. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Nebula Research & Development reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 23,391 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $226K.
  • Nebula Research & Development first reported a position in Aurinia Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Nebula Research & Development's Aurinia Pharmaceuticals position peaked at $226K in Q2 2023.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.